

Curriculum Vitae

Name in Full	Jae Jun Park
Country	Korea
Affiliation	Dept. of Internal Medicine, Severance Hospital, Yonsei University College of Medicine
Email	maranatta@gmail.com

Educational Background	
1999	B.S. Dept. of Chemical Engineering, Yonsei University, Seoul, Korea
2003	M.D. Yonsei University College of Medicine, Seoul, Korea
2010	M.S. Medical science, Graduate School, Yonsei University, Seoul, Korea
2013	Ph.D. Medical science, Graduate School, Yonsei University, Seoul, Korea

Professional Career	
2023.3 – Present:	Associate Professor of Internal Medicine, Division of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2019.3 – 2023.2:	Assistant Professor of Internal Medicine, Division of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2013.3– 2019.2:	Clinical Assistant Professor of Internal Medicine, Division of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2010.3 – 2013.2:	Clinical Assistant Professor, Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea
2008.3 - 2010.2:	Clinical and Research fellowship, Department of Internal Medicine, Division of Gastroenterology, Yonsei University Severance Hospital, Seoul, Korea
2004.3 - 2008.2:	Residency, Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, Korea
2003.3 - 2004.2:	Internship, Yonsei University Severance Hospital, Seoul, Korea

The logo for SGI 2024, with 'SGI' in a bold, yellow, sans-serif font and '2024' in a larger, outlined, yellow font.

The 17th Annual Meeting of
Society of Gastrointestinal Intervention

Leading the Way in GI Intervention: Collaboration, Innovation, Education

8 Tue – 9 Wed, October
Seoul Dragon City, Korea

Research Field
Small bowel disease
Colon cancer
Inflammatory bowel disease
Therapeutic endoscopy/Colonoscopy
Microbiota research

1. Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease. Won Moon, Jae Jun Park. *Korean J Gastroenterol* 2024; 83(6): 233-24 (Corresponding author)
2. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study. Kim K, Park JJ, Yoon H, Lee J, Kim KO, Kim ES, Kim SY, Boo SJ, Jung Y, Yoo JH, Hwang SW, Park SH, Yang SK, Ye BD; Scientific Committee of the Korean Association for the Study of Intestinal Diseases. *Aliment Pharmacol Ther*. 2024 Jun;59(12):1539-1550 (Co-first author)
3. Risk factors for post-polypectomy bleeding in patients with end-stage renal disease undergoing colonoscopic polypectomy. Ji JH, Kim HW, Park J, Park SJ, Cheon JH, Kim TI, Park JJ. *Surg Endosc*. 2023 Dec 11. doi: 10.1007/s00464-023-10626-5. Online ahead of print. (Corresponding author)
4. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis. Park JJ, Kim BC, Hong SP, Seo Y, Lee HS, Park YS, Na SY, Park SC, Park J, Kim JH, Moon CM, Huh KC, Park SJ, Cheon JH, Kim WH, Kim TI. *Cancer Prev Res (Phila)*. 2021 Jan 28. doi: 10.1158/1940-6207.CAPR-20-0580. (Co-first author)
5. The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis. Kim MA, Kim YH, Chun J, Lee HS, Park SJ, Cheon JH, Kim TI, Kim WH, Park JJ. *J Crohns Colitis*. 2020 Nov 11:jjaa225. doi: 10.1093/ecco-jcc/jjaa225. (Corresponding author)
6. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer. Chang JY, Kim JH, Kang J, Park Y, Park SJ, Cheon JH, Kim WH, Kim H, Park JJ, Kim TI. *Yonsei Med J*. 2020 Jul;61(7):572-578. doi: 10.3349/ymj.2020.61.7.572. (Co-corresponding author)
7. Predictive factors for inadequate bowel preparation using low-volume polyethylene glycol (PEG) plus ascorbic acid for an outpatient colonoscopy. Shin SY, Ga KS, Kim IY, Park YM, Jung DH, Kim JH, Youn YH, Park H, Park JJ. *Sci Rep*. 2019 Dec 23;9(1):19715. (Corresponding author)
8. Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease. Jae Jun Park. *J Rheum Dis* 2020; 27(3): 128-135 (Corresponding author)
9. Clinical outcomes and factors patients receiving related self-expandable metal stent insertion for to colonic perforations in malignant colorectal obstruction. Lee YJ, Yoon JY, Park JJ, Park SJ, Kim J, Yoon YH, Kim TI, Park H, Kim WH, Cheon JH. *Gastrointest Endosc*. 2018/87/1548-1557 (Co-corresponding author)
10. The association between *Helicobacter pylori* infection and the risk of advanced colorectal neoplasia may differ according to age and cigarette smoking. Park H, Park JJ, Park YM, Baik SJ, Lee HJ, Jung DH, Kim JH, Youn YH, Park H. *Helicobacter* 2018/23/e12477. (Corresponding author)
11. Impact of peritoneal carcinomatosis on clinical outcomes of patients receiving self-expanding metallic stents for malignant colorectal obstruction. Park JJ, Rhee K, Yoon JY, Park SJ, Kim JH, Kim J, Cheon JH, Yoon YH, Kim TI, Park H, Kim WH. *Endoscopy*. In press. (1st author)
12. A simple scoring model for advanced colorectal neoplasm in asymptomatic subjects aged 40-49 years. Park YM, Kim HS, Park JJ, Baik SJ, Youn YH, Kim JH, Park H. *BMC Gastroenterol*. 2017 Jan 9;17(1):7.

- (Corresponding author)
13. Second Korean guidelines for the management of Crohn's disease. Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H. *Intest Res.* 2017 /15/38-67. (1st author)
 14. Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. Lee HS, Park JJ, Kim SU, Lee JE, Leem GL, Kim Y, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. *Scand J Gastroenterol.* 2016 May;51(5):618-24. (Co-corresponding author)
 15. The Effects of an Extract of *Atractylodes Japonica* Rhizome, SKI3246 on Gastrointestinal Motility in Guinea Pigs. Park JJ, Chon NR, Lee YJ, Park H. *J Neurogastroenterol Motil.* 2015 Jul 30;21(3):352-60. (1st author)
 16. Predictive Factors for Endoscopic Visibility and Strategies for Pre-endoscopic Prokinetics Use in Patients with Upper Gastrointestinal Bleeding. Lim JU, Park JJ, Youn YH, Kim S, Jeon JW, Jung SW, Shin HP, Cha JM, Joo KR, Lee JI. *Dig Dis Sci.* 2015 Apr;60(4):957-65. (Corresponding author)
 17. Prevention and treatment of thromboembolism in patients with inflammatory bowel disease. Park JJ. *Korean J Gastroenterol.* 2015/65/151-158. (Corresponding author)
 18. Outcome predictors for intestinal Behçet's disease. Park JJ, Kim WH, Cheon JH. *Yonsei Med J.* 2013 Sep;54(5):1084-90. (1st author)

► Books

1. Atlas of inflammatory bowel disease 2015, Springer, Chapter 3. Differential Diagnosis: Intestinal Behçet's Disease, Chapter 4. Differential Diagnosis: Intestinal Tuberculosis
2. 염증성장질환 2016, 2023년 개정판발행. 대한의학서적. Chapter 5. 크론병의 진단
3. 소장내시경 2021 대한의학서적. Chapter 6. 기타 소장내시경-나선소장내시경
4. 캡슐내시경 2021 대한의학서적. PART III 소장 캡슐내시경의 임상적 적용. Chapter 3 염증성장질환.
5. 임상 소화기내시경학 2021 대한의학서적. Part 2. 하부위장관내시경. Chapter 2. 삽입과 관찰. ③ 염증성 병변 관찰 요령.
6. Small Intestine Disease. 2022. Springer, Chapter Cryptogenic Multifocal Ulcerous Stenosing Enteritis
7. Gastrointestinal Cancer. A Comprehensive Guide to Diagnosis and Management 2023, Sprangle, Small bowel cancer part, Chapter Epidemiology and Prevention. I-1. Epidemiology and Risk Factors.